In keeping with our cognitive burden hypothesis, we found that – controlling for morbidity and time since dementia diagnosis – community-dwelling people with dementia were more likely to receive both potentially harmful (benzodiazepine and antipsychotic) and potentially beneficial (cholinesterase inhibitor) prescriptions from their PCP if that physician saw ≥ 30 versus < 20 patients per day. The gene discussed is BCHE; the disease is dementia.